Protective immunity induced by B7.1+IL-12 transfected tumor cells is abrogated by tumor growth in an immune privileged site

P. W. Chen, T. Uno, D. G. Geer, E. R. Podack, B. R. Ksander

Research output: Contribution to journalArticlepeer-review

Abstract

Mice immunized with B7.1+IL-12 transfected tumor cells possess systemic anti-tumor immunity that protects mice from a second subcutaneous tumor challenge of untransfected cells. This study determines if these immunized mice are protected from a second tumor challenge delivered to an immunologically privileged site. Our previous results indicated that tumors growing within the immunologically privileged anterior chamber of the eye (AC) of naive mice induce systemic T cell tolerance. In these experiments we determined if tolerance could be imposed after mice were previously sensitized. DBA/2 mice were given a subcutaneous immunization with 1 × 106 P815 B7.1+IL-12 cells. One month later, mice received a second tumor challenge of untransfected P815 cells. When challenged in the non-privileged site, mice eliminated a tumor dose as large as 2 x 106 cells. By contrast, mice challenged in an immune-privileged site were unable to eliminate a tumor dose as low as 2 × 103 cells. We conclude that tumors within immune privileged sites induce systemic tolerance in pre-sensitized mice. These results imply that subcutaneous tumor vaccines that successfully protect from métastases that develop at non-privileged sites will not be effective if tumor cells subsequently migrate to immune privilege sites. NIH EY08112 and EY09294.

Original languageEnglish (US)
Pages (from-to)A1164
JournalFASEB Journal
Volume10
Issue number6
StatePublished - Dec 1 1996

ASJC Scopus subject areas

  • Biotechnology
  • Biochemistry
  • Molecular Biology
  • Genetics

Fingerprint

Dive into the research topics of 'Protective immunity induced by B7.1+IL-12 transfected tumor cells is abrogated by tumor growth in an immune privileged site'. Together they form a unique fingerprint.

Cite this